Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for X-396

2 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Treatment

    VICCTHN1244

    07/25/2012

    Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors


    Print this page for your doctor